Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock / PopTika Iveric Bio (NASDAQ: ISEE ) stock is rising higher on Tuesday after the biopharmaceutical company revealed positive results from a Phase 3 clinical trial . That trial covered the...
September has historically been a difficult month for stock market investors, but major market benchmarks looked poised to gain ground on Tuesday morning. The Nasdaq Composite (NASDAQINDEX: ^IXIC) opened higher by about half a percent, and other stock indexes showed similar gains he...
Iveric bio ( NASDAQ: ISEE ) said its medicine Zimura met the main goal of a second phase 3 trial called GATHER2 to treat an eye disease called geographic atrophy (GA). GA is a progressive degeneration of the macula, as part of late-stage age-related macular deg...
- Primary Endpoint Met with 14.3% Reduction (p-value = 0.0064) in Mean Rate of Growth (Slope) in GA Area Over 12 Months Using Square Root Transformation; 17.7% Reduction (p-value = 0.0039) Using Observed GA Area - - Statistically Significant Result with Favorable Safety Profil...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in a panel discussion titled, “Differentiation in Emerging Treatments for GA dAMD -- Perspectives From ISEE,” at the H.C. Wainwright 2 nd Annual Ophthalmology Vi...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biopharmaceutical companies have been struggling since 2021 and that narrative isn’t immediately changing. However, not every firm deserves this fate. In fact, investors can find great opportunities with “chea...
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Keith Westby, Chief Operating Officer, will participate in a fireside chat at the Wedbush PacGrow Healthcare Conference 2022 on Tuesday, August 9, 2022, at 1:45 p.m. Eastern Time. ...
IVERIC bio, Inc. (ISEE) Q2 2022 Earnings Conference Call July 26, 2022, 08:00 AM ET Company Participants Kathy Galante - SVP of IR Glenn Sblendorio - CEO Pravin Dugel - President Keith Westby - COO David Carroll - CFO Dhaval Desai - Chief Development ...
Image source: The Motley Fool. IVERIC bio, Inc. (NASDAQ: ISEE) Q2 2022 Earnings Call Jul 26, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: IVERIC bio, Inc. (ISEE) Q2 2022 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Astellas Completes Acquisition of Iveric Bio PR Newswire TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has successfully completed the acquisit...
Shares of IVERIC bio, Inc. (NASDAQ: ISEE) traded at a new 52-week high today and are currently trading at $39.73. So far today, approximately 1.78M shares have been exchanged, as compared to an average 30-day volume of 5.04M shares. IVERIC bio, Inc., a biopharmaceutical company, discovers and...
IVERIC bio, Inc. (NASDAQ: ISEE) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 1.93% on the day to $38.77. IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal disease...